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ABSTRACT: Kinetoplastid parasites have caused human disease for millennia. Signiﬁcant achievements have been made
toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African
trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a
tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in
more than three decades, and more work is needed to discover safe and eﬀective therapies for patients with Chagas disease and
leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host−parasite interaction may
provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who
met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
Nearly a billion people are at risk from the group of vector-borne kinetoplastid diseases comprised of Chagas
disease, leishmaniasis, and human African trypanosomiasis
(HAT, also known as sleeping sickness). These ancient
parasitic illnesses have burdened humans for thousands of
years, as evidenced by Trypanosoma DNA sequences found in
South American mummies.1 In the current era, kinetoplastid
diseases cause an estimated 30 000 deaths annually and induce
crippling morbidities in millions more.
There is reason to be optimistic about trends concerning
HAT. Public and private partners have jointly tackled the
disease in recent decades, with the World Health Organization
(WHO) coordinating public health activities and the Drugs for
Neglected Diseases initiative (DNDi) directing global eﬀorts
for new therapies. The introduction of nifurtimox-eﬂornithine
therapy in 2009 was a pivotal milestone, which was followed
recently by the demonstrated eﬃcacy of oral fexinidazole2 for
late-stage disease. (Approval for use is now pending assessment
by medicine regulatory agencies.) Fewer than 1500 new cases
were reported to WHO in 2017, making disease elimination a
tangible goal.
Successes in combating HAT are encouraging and contrast
with slower progress in containing other kinetoplastid diseases.
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Most of the current kinetoplastid drugs are repurposed and are
often not potent enough to render a sterile cure (i.e., to
eliminate all parasites). Safe, eﬀective, short-course practical
therapies are urgently needed for Chagas disease and
leishmaniasis yet remain elusive.
To understand the present-day challenges and opportunities
related to new medicines for Chagas disease, visceral
leishmaniasis (VL), and cutaneous leishmaniasis (CL), the
Novartis Institute for Tropical Diseases convened a multi-
disciplinary group of scientiﬁc and medical specialists in
parasitology, immunology, and drug discovery in June 2018.
The scope of the discussion encompassed unmet medical
needs, the global pipeline of preclinical drug candidates,
parasite biology, assays, models, and the potential use of novel
immunomodulatory and adjunct therapies to target disease
sequelae. This Viewpoint summarizes key workshop learnings.
■ CURRENT DRUGS: OLD, TOXIC, AND OFTEN
INEFFECTIVE
Chagas disease, which is endemic in the Americas, is caused by
Trypanosoma cruzi. Inoculation typically occurs through
infected feces from the triatomine bug, which is scratched or
rubbed into the skin or mucosa. Transmission also takes place
through blood transfusion and congenital and oral routes. The
pathogenesis of Chagas disease is not fully understood, and it is
currently impossible to predict which fraction of the patient
population (approximately 30%) will develop the serious
cardiac or gastrointestinal sequelae that appear years after the
initial infection (Figure 1). Sudden death from chronic Chagas
cardiomyopathy is an all too common outcome. Two drugs,
nitroheterocyclic agents benznidazole and nifurtimox, are used
for the treatment of Chagas disease; both were developed
decades ago, are contraindicated during pregnancy, and can
have serious adverse eﬀects that substantially restrict their use.
Benznidazole is the better-tolerated option in adults, although
15−30% patients are unable to ﬁnish the standard 60-day
course, mainly because of skin and nervous system
complications. In children, nifurtimox is better tolerated than
benznidazole.
In both acute and chronic T. cruzi infection, treatment
reduces the parasite load and can yield clearance from blood
using available assays (e.g., PCR). Even so, in some cases,
parasites presumably may persist intracellularly, and it is
unclear in adults how the reductions in the parasite load
modulate the severity of chronic disease in the absence of
complete parasite clearance. Current drugs are inadequate
because they fail too often and are not dependable. However,
WHO recommends oﬀ-label use of benznidazole for the
treatment of chronically infected patients, even though its
eﬃcacy in later stages of the disease is debatable. A large study
of patients with chronic Chagas cardiomyopathy (the
BENEFIT trial) demonstrated that benznidazole treatment
reduced the parasite burden but did not signiﬁcantly reduce
disease progression. However, most subjects had New York
Heart Association class I (largely asymptomatic) heart disease,
which may have confounded the ﬁndings.3 Some non-
randomized, unblinded studies using benznidazole in inde-
terminate patients without heart failure showed reduced
disease progression, emphasizing the need for controlled
randomized studies for indeterminate patients.4
Similarly, the approved therapeutic arsenal for leishmaniasis
has important limitations. Leishmaniasis is distributed across
the tropics and subtropics, though a majority of VL cases are
reported in only seven countries: Brazil, Ethiopia, Kenya,
Somalia, Sudan, South Sudan, and India. Patients succumb to
VL gradually over a period of 2 years. Anorexia and
pancytopenia give rise to wasting and increased susceptibility
to bacterial superinfections. VL is fatal without treatment, and
even those who undergo therapy remain at risk of a disﬁguring
dermal form of relapsing disease called post kala-azar dermal
Figure 1. Clinical manifestations of kinetoplastid diseases and opportunities for intervention.
ACS Infectious Diseases Viewpoint
DOI: 10.1021/acsinfecdis.8b00298
ACS Infect. Dis. 2019, 5, 152−157
153
leishmaniasis (PKDL) that may also contribute to continued
disease transmission (Figure 1). CL has a higher global burden
than VL, with the greatest prevalence in Africa, the
Mediterranean, and South America. It does not cause systemic
morbidities or death but can result in grievous disﬁguration
and stigma. Drugs targeting Leishmania parasites have generally
been repurposed from other indications. Antimonials,
amphotericin B, paromomycin sulfate, and miltefosine have
variable eﬃcacy against the more than 20 Leishmania species
that cause disease. While WHO-recommended treatment
regimens for VL on the Indian subcontinent include liposomal
amphotericin B or oral miltefosine, these medicines are poorly
eﬀective in patients in other global regions. Treatment courses
are generally long, require hospitalization, and have signiﬁcant
toxicities that mandate frequent monitoring. Diﬀerences in the
treatment protocol by region, high costs, and low availability of
some drugs understandably stretch the limits of under-
resourced health systems in countries where these diseases
are endemic.
■ THE ANTIPARASITIC PIPELINE IS FILLING, BUT
THERE ARE GAPS
Antiparasitics are the cornerstone of therapy for kinetoplastid
diseases. It is well accepted that the clinical event cascades in
Chagas disease and leishmaniasis are induced by the presence
of parasites, and evidence suggests that eliminating parasites as
early as possible after infection could mitigate severe disease.
Unfortunately, the current preclinical pipeline for Chagas
disease treatments is meager. Only three classes of compounds
have been shown to achieve high cure rates in stringent mouse
models of infection: nitroimidazoles (e.g., fexinidazole,
currently in phase II), oxaboroles (e.g., DNDi-6148, active
against both leishmaniasis and Chagas), and proteasome
inhibitors (e.g., GNF67025). The future is brighter in drug
discovery for leishmaniasis, where there are at least six
candidates in preclinical or clinical phases that have ﬁve
distinct mechanisms of action.6
Proposed target product proﬁles for new drugs are listed in
Box 1. For Chagas disease, medicines should achieve cures that
prevent the development of chronic disease. Any treatment to
be given beyond the acute stage must be simple to administer
and safe because patients in the indeterminate phase typically
feel healthy and are unlikely to comply with a complex or
poorly tolerated drug regimen. In leishmaniasis, a short-course
therapy that achieves a relapse-free cure with no or minor
adverse eﬀects would be ideal, but even a medicine with
eﬃcacy similar to that of current drugs and improved safety
would be a step forward.
Whether a sterile cure is essential is a topic of debate. Some
parasitologists advocate strongly that a sterile cure must be
achieved in Chagas disease to prevent the reproliferation of
parasites and enduring pathogenicity. A sterile cure may not be
critical for VL and CL. Reducing the parasite load in these
infections could be suﬃcient if the host immune system can
complete the job of parasite control or clearance. A sterile cure
is more likely needed for PKDL (which appears to result from
latent parasites) and for VL in individuals with HIV
coinfection or other immunodeﬁciency syndromes. A con-
dition known as leishmaniasis recidivans in CL may also result
from the recrudescence of latent parasites that survive therapy.
■ NEW INSIGHTS INTO DISEASE BIOLOGY WILL
INDICATE THE NEED FOR NEW MODELS
Given how little we know about the biology of T. cruzi and
Leishmania species and the lack of validated drug targets, it is
not surprising that most current pipeline compounds
originated from phenotypic screens. Assays are available to
test the growth inhibition of amastigotes for T. cruzi
(intracellular) and Leishmania (intracellular and axenic), and
these are compatible with high-throughput screening. It may
be important to evaluate the antiparasitic eﬀect of compounds
by using intracellular parasites grown in disease-relevant
tissues. Cidality, time-to-kill kinetics, and washout assays may
be used to further enhance the conﬁdence of hits and to assist
prioritization.
Highly sensitive in vivo imaging with bioluminescent T. cruzi
that enables the monitoring of the mouse parasite burden in
real time has highlighted how the parasite load varies by tissue
type over time.7 Furthermore, this model has predictive power.
It demonstrated the limited eﬃcacy of posaconazole, a Chagas
disease drug candidate that had previously shown potency in
animal models but has failed to consistently eliminate
parasitemia in patients. By comparison, benznidazole was
shown to be eﬃcacious in both mice and humans.8 Similarly,
novel murine and hamster models for VL and CL using
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bioluminescent parasites have improved our understanding of
disease progression. New chemical entities should be tested in
mouse models with speciﬁc questions in mind, such as how the
treatment duration and curative exposures could translate from
mice to humans.
An important unknown for Chagas disease is the role played
by amastigotes that spontaneously adopt a “persister”
phenotype. These nonreplicative and phenotypically drug-
resistant forms of the parasite are later able to diﬀerentiate to
trypomastigotes and reinfect new host cells.8 Future work is
needed to understand how the development of persistent
forms is triggered, if they are metabolically active, whether they
can be forced out of dormancy, and what their role is in disease
progression. In the meantime, screening against persistent
parasites to ﬁnd novel inhibitors would be beneﬁcial.9
Persistence in Leishmania may also be a concern. Persistent
L. mexicana and L. major parasites have been reported in
mouse models,10,11 although similar forms have not yet been
sought in animals for L. donovani or L. infantum. However,
nonreplicating L. donovani were identiﬁed in a macrophage
model, and these could represent persister-type cells, the
existence of which is implicated through the recrudescence that
can occur following VL treatment and manifests as PKDL.12
■ IMMUNE MODULATION HAS PROMISE IN
ANTIPARASITIC THERAPY
Kinetoplastid infections provoke robust innate and adaptive
immune reactions, which can be protective or disease-
promoting. This provides a rationale for investigating host-
directed strategies such as immune modulators as an add-on to
antiparasitic therapy. Lessons from immuno-oncology may
oﬀer a roadmap. Indeed, there are similarities in the dynamics
of host−tumor and host−parasite interactions. Both tumor
cells and cells harboring intracellular parasites are perceived by
the immune system as foreign, both retain features of normal
cells that could trigger an immune tolerance, and both can
create a microenvironment that facilitates immune escape and
promotes disease progression. In certain types of cancer,
adding immunotherapy to cytotoxic chemotherapy improves
survival. For example, a monoclonal antibody that binds to T
cells and blocks their inhibition by tumor cells is now part of
the ﬁrst-line treatment for some lung cancers.13 An analogous
approach could conceivably help antiparasitic medicines to
work more quickly, more eﬀectively, or with less variability.
Harnessing the immune system to treat kinetoplastid
diseases is not a new idea. Beginning in the early 1990s,
interferon-gamma was tested in VL and CL patients (usually in
combination with antimony), with mixed results. Interleukin
(IL)-10 has been studied extensively in VL. It appears to
promote parasite growth, and experimental models suggest that
the IL-10 blockade can reduce disease progression.14,15 A
clinical trial with a humanized anti-IL-10 antibody was planned
but later withdrawn due to problems in securing quality drug
for the study (NCT01437020). IL-10 neutralization may also
provide a beneﬁt in CL.16 Additionally, TLR9 agonist CpG
D35 is currently undergoing preclinical development in
preparation for clinical trials for CL.6
In Chagas disease, the association of several pro- and anti-
inﬂammatory cytokines has been observed with cardiac and
indeterminate forms of the disease, respectively.17 Some
immunomodulation strategies postulated for Chagas disease
include limiting regulatory T cells and increasing IL-17,18
although overall there is less evidence to support immune
modulation in Chagas disease compared with leishmaniasis.
Naturally, there are challenges to testing and deploying
immunotherapies. Success or failure in experimental models is
not necessarily predictive of outcomes in humans. Patients
with leishmaniasis are at high risk of coinfection with bacteria;
therefore, modulating immunity in these populations will
require careful safety monitoring. Even if immunotherapy is
successful in enhancing the response to treatment in acute
disease, there are no tools to deﬁnitively assess latent infection.
Finally, the immune system is dynamic and changes with age,
pregnancy, coinfections, and other conditions, which would
need to be considered.
■ ADJUNCT THERAPIES ARE ALSO NECESSARY IN
THE CLINICAL ARMORY
Adjunct therapies that improve outcomes including quality of
life should be pursued in parallel with work to discover
parasite-speciﬁc agents. These include medicines to improve
wound healing in CL, to address nutrition or coinfection
complications in VL, and to better manage cardiovascular and
gastrointestinal complications in Chagas disease. This also
applies to preventative or therapeutic vaccines, which are in
various phases of development.
Progress toward adjunct therapies is hampered in part by
our limited understanding of many features of disease biology.
There are, however, illustrative examples. In CL, the disease is
in large part mediated by the inﬂammatory immune response.
For example, lesions from L. braziliensis patients have few
parasites but severe ulceration, and experimental studies
indicate that a blockade of IL-1β or the NLRP3 inﬂammasome
may ameliorate the disease in these patients.19 There is
evidence that wound treatment with pharmaceutical sodium
chlorite 0.045% or radio-frequency-induced heat therapy has
clinical beneﬁts for CL.20 In chronic Chagas cardiomyopathy,
patients generally suﬀer worse outcomes than those with heart
failure from other causes, despite the fact that Chagas disease
patients are usually younger and have fewer comorbidities.21
Recently, angiotensin receptor−neprilysin inhibition was found
to reduce mortality and hospitalization in a large group of heart
failure patients with a reduced ejection fraction, including a
subgroup of patients with Chagas disease.22 Future work will
be needed to determine the speciﬁc implications for Chagas
disease patients.
■ SUMMARY
While there have been substantial advances in recent years to
address kinetoplastid diseases, on the whole these conditions
remain severely neglected across the domains of health policy,
advocacy, funding, and research. For HAT, more work is
needed to ensure that the gains realized are not lost. With
respect to ﬁnding safe and eﬀective new therapies for Chagas
disease and leishmaniasis, we highlight several key priorities.
To start, the fundamental pathobiology of these diseases must
be further demystiﬁed to pave the way for targeted treatments;
the discovery of persister parasites is a sobering reminder that
we have much to learn before deﬁnitive medicines can be
generated. Novel tools will be needed to successfully validate
clinical candidates in patients, including biomarkers capable of
measuring intracellular parasite clearance and predicting the
clinical beneﬁt without the need for extended follow-up. The
potential beneﬁts in kinetoplastid diseases for immune
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modulation and adjunct therapies need to be carefully
evaluated. Finally, we advocate continued and even greater
multidisciplinary collaboration. In the face of limited resources,
with an all too small scientiﬁc and medical community focused
on these complex diseases, harmonized research and develop-
ment strategies will be essential to accelerating progress toward
the common good of transformative new therapies for patients.
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